Stoke Therapeutics, Inc. Earnings Per Share, Basic and Diluted
Stoke Therapeutics, Inc. (STOK) reported Earnings Per Share, Basic and Diluted of -$0.66 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-10
- Stoke Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.66.
- Stoke Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.66.
- Stoke Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.61.
- Stoke Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.60.
- Stoke Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2021 was -$2.34.
- Stoke Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2020 was -$1.56.
- Stoke Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2019 was -$1.80.
- Stoke Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2018 was -$17.65.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.66 10-Q · filed 2022-05-10 | -$1.32 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$1.94 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$2.54 derived: net income ÷ weighted average shares · filed 2023-11-07 |
| 2021-12-31 | -$0.66 derived: net income ÷ weighted average shares · filed 2023-03-06 | -$1.28 derived: net income ÷ weighted average shares · filed 2023-03-06 | -$1.88 derived: net income ÷ weighted average shares · filed 2023-03-06 | -$2.34 10-K · filed 2022-03-10 |
| 2021-09-30 | -$0.61 10-Q · filed 2021-11-08 | -$1.21 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$1.67 10-Q · filed 2021-11-08 | -$2.09 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2021-06-30 | -$0.60 10-Q · filed 2021-08-10 | -$1.06 10-Q · filed 2021-08-10 | -$1.48 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$1.89 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2021-03-31 | -$0.46 10-Q · filed 2022-05-10 | -$0.87 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$1.29 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$1.68 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2020-12-31 | -$0.42 10-K · filed 2021-03-09 | -$0.83 derived: net income ÷ weighted average shares · filed 2022-03-10 | -$1.22 derived: net income ÷ weighted average shares · filed 2022-03-10 | -$1.56 10-K · filed 2022-03-10 |
| 2020-09-30 | -$0.41 10-Q · filed 2021-11-08 | -$0.80 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$1.14 10-Q · filed 2021-11-08 | -$1.45 derived: net income ÷ weighted average shares · filed 2021-11-08 |
| 2020-06-30 | -$0.39 10-Q · filed 2021-08-10 | -$0.73 10-Q · filed 2021-08-10 | -$1.04 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$1.30 derived: net income ÷ weighted average shares · filed 2021-11-08 |
| 2020-03-31 | -$0.34 10-Q · filed 2021-05-10 | -$0.64 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$0.91 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$1.45 derived: net income ÷ weighted average shares · filed 2021-11-08 |
| 2019-12-31 | -$0.31 10-K · filed 2021-03-09 | -$0.57 derived: net income ÷ weighted average shares · filed 2021-03-09 | -$1.13 derived: net income ÷ weighted average shares · filed 2021-03-09 | -$1.80 10-K · filed 2021-03-09 |
| 2019-09-30 | -$0.26 10-K · filed 2021-03-09 | -$0.87 derived: net income ÷ weighted average shares · filed 2021-03-09 | -$1.71 10-Q · filed 2020-11-12 | -$2.69 derived: net income ÷ weighted average shares · filed 2021-03-09 |
| 2019-06-30 | -$1.54 10-K · filed 2021-03-09 | -$4.57 10-Q · filed 2020-08-10 | -$8.02 derived: net income ÷ weighted average shares · filed 2021-03-09 | -$11.48 derived: net income ÷ weighted average shares · filed 2021-03-09 |
| 2019-03-31 | -$6.89 10-K · filed 2021-03-09 | -$12.58 derived: net income ÷ weighted average shares · filed 2021-03-09 | -$17.46 derived: net income ÷ weighted average shares · filed 2021-03-09 | -$21.92 derived: net income ÷ weighted average shares · filed 2021-03-09 |
| 2018-12-31 | -$6.05 10-K · filed 2020-03-23 | -$10.42 derived: net income ÷ weighted average shares · filed 2020-03-23 | -$14.80 derived: net income ÷ weighted average shares · filed 2020-03-23 | -$17.65 10-K · filed 2020-03-23 |
| 2018-09-30 | -$4.75 10-K · filed 2020-03-23 | -$9.10 derived: net income ÷ weighted average shares · filed 2020-03-23 | -$11.90 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$4.36 10-K · filed 2020-03-23 | -$7.14 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | -$2.78 10-K · filed 2020-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |